Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.

Vodosek Hojs, Nina; Bevc, Sebastjan; Ekart, Robert; Piko, Nejc; Petreski, Tadej; Hojs, Radovan

Vodosek Hojs, Nina; Bevc, Sebastjan; Ekart, Robert; Piko, Nejc; Petreski, Tadej; Hojs, Radovan.

Afiliação

Vodosek Hojs N; Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.
Bevc S; Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.
Ekart R; Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Piko N; Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Petreski T; Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.
Hojs R; Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.

Pharmaceuticals (Basel) ; 14(6)2021 Jun 11.

Article em En | MEDLINE | ID: mdl-34208285

Palavras-chave

apararenone; chronic kidney disease; diabetic kidney disease; eplerenone; esaxerenone; finerenone; mineralocorticoid receptor antagonists; spironolactone

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Eslovênia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google